Beyond Air Inc. (XAIR)

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

undefined

undefined%

At close: undefined

0.46

-1.15%

After-hours Dec 13, 2024, 06:53 PM EST

Company Description

Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company.

The company engages in the development of LungFit platform, a nitric oxide generator and delivery system.

It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.

The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria.

The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.

Beyond Air, Inc. is based in Garden City, New York.

Beyond Air Inc.

Country	United States
IPO Date	Jun 12, 2018
Industry	Medical - Devices
Sector	Healthcare
Employees	107
CEO	Steven Adam Lisi

Contact Details

Address: 900 Stewart Avenue Garden City, New York United States
Website	https://www.beyondair.net

Stock Details

Ticker Symbol	XAIR
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	0001641631
CUSIP Number	08862L103
ISIN Number	US08862L1035
Employer ID	47-3812456
SIC Code	3841

Key Executives

Name	Position
Amir Avniel	Chief Executive Officer of NeuroNOS
Steven Adam Lisi	Chief Executive Officer & Chairman of the Board
Douglas Quinton Larson	Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Michael A. Gaul	Chief Operating Officer
Adam Newman	Corporate Secretary
David R. Webster	Chief Commercial Officer
Dr. Andrew R. Colin M.D.	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
Dr. John Jett Ph.D.	Head of Research & Clinical Development
Edward Barger	Head of Investor Relations

Latest SEC Filings

Date	Type	Title
Dec 06, 2024	8-K	Current Report
Dec 03, 2024	8-K	Current Report
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing
Nov 26, 2024	4	Filing

View All SEC Filings